8.1K
Articles
237.5K
Citations
3.1
avg. Impact Factor
199
h-index

Most Cited Articles of Division of Hematology in 2004

TitleJournalYearCitations
Multiple myelomaNew England Journal of Medicine20041.2K
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosisJournal of Clinical Oncology2004593
Genetics and cytogenetics of multiple myeloma: a workshop reportCancer Research2004560
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancerJournal of Clinical Oncology2004544
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood2004266
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaBlood2004248
Clinical cardiac tolerability of trastuzumabJournal of Clinical Oncology2004224
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLLBlood2004195
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyBlood2004193
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcomeBlood2004193
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemiaBlood2004177
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood2004174
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Leukemia and Lymphoma2004161
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyCancer2004154
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivoBlood2004148
Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decadesCancer2004145
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionBlood2004123
Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromeJournal of Biological Chemistry2004122
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myelomaBlood2004110
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialJournal of Clinical Oncology2004108
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateBone Marrow Transplantation200490
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myelomaLeukemia200488
Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphomaBone Marrow Transplantation200480
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphomaLeukemia200479
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia200479